A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis

NCT07465120 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Atopic Dermatitis

Interventions

DRUG: CMS-D001 50mg
DRUG: CMS-D001 100mg
DRUG: CMS-D001 200mg
DRUG: Placebo

Sponsor

Dermavon Holdings Limited